Study Shows 77% Reduction in Antibiotic Use After Sinus Surgery with Ondine's Steriwave

Ondine Biomedical Inc., a Canadian life sciences firm, revealed that a study in the UK found a significant decline in antibiotic use following sinus surgeries when Steriwave® was utilized for pre-surgical nasal decolonization. The use of antibiotics fell from 22% to under 5%, marking a 77% reduction. This advancement comes as a part of Ondine's efforts to combat healthcare-associated infections (HAIs) using light-activated antimicrobial treatments.

Professor Claire Hopkins, a leading figure in rhinology, shared her positive outcomes from incorporating Steriwave in her endoscopic sinus surgery protocols at London Bridge Hospital since 2021. Her clinical practice saw a significant drop in post-operative infections requiring antibiotics, which aligns with global efforts to reduce antibiotic resistance.

Ondine’s CEO, Carolyn Cross, emphasized the importance of this achievement amidst growing drug resistance concerns. She highlighted Steriwave's role in reducing antibiotic use while maintaining patient safety and effectiveness against pathogens without generating resistance or adverse effects on the nasal microbiome. Furthermore, Steriwave has demonstrated compelling results in over 150,000 patients and was named a finalist in the 2024 SPIE Prism Awards.